| abstract |
This disclosure relates to a pharmaceutical composition comprising: (a) a stabilized pharmaceutical dosage form comprising atartan or a pharmaceutically acceptable salt thereof, and optionally other therapeutic agents; (b) methods of treating nephropathy, chronic kidney disease, and / or other conditions using such pharmaceutical dosage forms; (c) a kit comprising a second pharmaceutical dosage form comprising such a pharmaceutical dosage form, and optionally another therapeutic dosage form; (d) a method for producing such a pharmaceutical dosage form; And (e) a pharmaceutical dosage form prepared by such a method. |